Key Highlights

  • The third quarter net loss totaled USD 208.4 million, or USD 0.26 per share, versus USD 231.8 million, or USD 0.31, a year earlier, and the nine-month loss reached USD 613.5 million.
  • The USD 2.0 billion gross Equity Investment from AstraZeneca closed on October 5, 2026 through Class A convertible preferred stock, convertible into roughly 109.0 million common shares.
  • The FDA assigned a goal action date of November 14, 2026 for the ivonescimab BLA and stated that a statistically significant overall survival benefit is required to support Marketing authorization.
  • Cash and cash equivalents were USD 150.8 million and short-term investments were USD 479.0 million at September 30, 2026, following nine-month operating cash use of USD 423.2 million.

AstraZeneca Preferred Stock Reshapes the Funding Picture

Summit Therapeutics (NASDAQ:SMMT) published its quarterly figures on November 4, 2026. On September 28, 2026 the company agreed to sell roughly 108,955 shares of Class A convertible preferred to AstraZeneca at USD 18,356.14 apiece, each convertible into 1,000 common shares at USD 18.3561. The sale closed October 5, 2026, bringing in USD 2.0 billion before issuance costs. Conversion requires the antitrust Waiting Period to lapse and Shareholder approval to raise authorized common shares by 1.0 billion. Management concluded that the proceeds cover at least 12 months of operating needs. Summit also agreed to register resale of the conversion shares within 60 days of closing, which adds a large new holder to the register, a different route from the at-the-market sales used earlier this year.

Lower G&A Narrows the Loss While R&D Keeps Rising

Research and development expense went up to USD 169.1 million from USD 131.1 million, whereas general and administrative costs dropped to USD 45.5 million from USD 103.1 million. Total operating expenses were USD 214.6 million against USD 234.2 million, and other income reached USD 6.2 million. Nine-month G&A was USD 170.8 million, down from USD 479.1 million. The company is advancing ivonescimab, a cancer drug candidate, and its accumulated Deficit stands at USD 2.9 billion. In the quarter it also sold 6.2 million shares through an at-the-market program for USD 92.8 million net, with about USD 354.3 million of capacity remaining.

The November 14 FDA Date and the Survival Question

Summit Therapeutics (NASDAQ:SMMT) has a BLA seeking approval of ivonescimab with chemotherapy for EGFR-mutated non-small cell lung cancer. The company acknowledges the HARMONi study did not reach statistical significance on overall survival, and the FDA noted progression-free survival results may fall short. Management still considers the benefit-risk profile favorable. HARMONi-3, a Phase III comparison against pembrolizumab regimens, has finished enrolling. Key risks are the FDA outcome, dilution from conversion and ongoing losses, and the company says it will need additional Capital until substantial Revenue arrives. Nine-month R&D spending was USD 459.5 million versus USD 390.4 million, and cash plus short-term investments before the deal totaled USD 629.8 million, a calculated figure. No stock price data was in the filing.

Where Things Stand

Summit secured the money by selling convertible preferred stock to AstraZeneca, a deal that closed after quarter end and extends its runway even as losses run near USD 200 million a quarter. The FDA goal date of November 14, 2026 remains the central test, with the survival question at its core, and any conversion would add about 109.0 million common shares. The accumulated deficit reached USD 2.9 billion, and the filing gave no stock price information.